Lung cancer combo trial halted early

NCT ID NCT04619433

Terminated Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 27 times

Summary

This study tested a combination of three drugs—SHR-1210, famitinib, and chemotherapy—in people with advanced non-squamous non-small-cell lung cancer that had not been treated before. The goal was to see if the combination was safe and effective. The trial was stopped early and included 48 adults aged 18 to 70.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beijing Cancer Hosipital

Beijing, Beijing Municipality, 100089, China
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Hubei Cancer Hospita

Wuhan, Hubei, 430079, China
Shanghai Lung Hospital

Shanghai, Shanghai Municipality, 200433, China
Shengjing Hospita of China Medical University

Shenyang, Liaoning, 110022, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China
West China Hospital，Sichuan University

Chengdu, Sichuan, 610000, China

Conditions

Explore the condition pages connected to this study.

NON SQUAMOUS NON-SMALL CELL LUNG CANCER NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER